Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma

Inclusion Criteria: 1. histologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis of HCC according to American association for the study of liver diseases （AASLD）-guidelines or clinical diagnosis criteria based on Alpha Fetoprotein （AFP), and radiological images proposed by Liver Cancer Society, Chinese Anti-Cancer Association; 2. no clinically distant metastasis; 3. the tumor is away from gastro-intestinal (GI) tract (\>1cm); 4. Child Push score A,technically unresectable, or medically inoperable; maximal tumor size is less than 10 cm; 5. age ≥ 18 and \<80 years of age; 6. Karnofsky Performance Score ≥ 70; 7. No previous invasive cancer (within 5 years before the HCC diagnosis)except for skin non-melanoma cancer or non muscle invasive bladder cancer; Ability to understand character and individual consequences of the clinical trial; 8. Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial; Exclusion Criteria: 1. Distant metastasis (M1); 2. maximal tumor size is more than 10 cm; 3. tumor invading adjacent gastrointestine (T4); 4. Child push score B or C; 5. Previous hepatic radiotherapy; 6. Severe systemic disorders; 7. Previous malignancy (within 5 years) except for skin non-melanoma cancer or 3-year disease free interval from previous malignancy like in situ cervix cancer or non muscle invasive bladder cancer; 8. Non conformity of the radiotherapy dose distribution when compared to the dose constraints; 9. Psychiatric disorders or any other condition that can make unreliable the informed consent;